There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amarin (AMRN) and Corvus Pharmaceuticals (CRVS) with bullish sentiments.
Amarin (AMRN)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Amarin, with a price target of $10.00. The company’s shares closed last Thursday at $5.24.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 18.8% and a 51.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
Currently, the analyst consensus on Amarin is a Moderate Buy with an average price target of $10.50, which is a 99.2% upside from current levels. In a report issued on April 16, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $10.00 price target.
See today’s analyst top recommended stocks >>
Corvus Pharmaceuticals (CRVS)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Corvus Pharmaceuticals, with a price target of $9.50. The company’s shares closed last Thursday at $2.82, close to its 52-week low of $2.12.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 35.9% and a 51.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Cellectar Biosciences, and Trillium Therapeutics.
Currently, the analyst consensus on Corvus Pharmaceuticals is a Moderate Buy with an average price target of $6.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
